CAR-T Evaluation Form

E-Conference: How I Manage CAR-T Therapies and Bispecific Antibodies for My Patients
September 6-9, 2021 – #ESHCART2021
Chairpersons: Peter Borchmann (Cologne), Ulrich Jäger (Vienna), Marie José Kersten (Amsterdam)

Step 1 of 4

25%

EVALUATION SHEET

Work Place (Country):(Required)

Years of professional experience:

1-5 Years

5-10 Years

10-20 Years

20 Years and more

Q1: Are you fully trained OR in-training?

Fully Trained: MD

Fully Trained: MD-PhD

Fully Trained: Post Doctoral Researcher

Fully Trained: PhD

Fully Trained: Allied Health Professional

Fully Trained: Corporate

In-training: Resident

In-training: Doctoral Student

In-training: Allied Health Professional

Other:

Q1 Other(Required)

Q2: Your principal activity?

Patient Care

Clinical Research

Other Research

Teaching/Training

Other:

Q2 Other(Required)

Q3: What made you attend this conference?(Required)

Topics

Faculty

Virtual format

Timing

Invitation

Other:

Q3 Other(Required)

Q4: How were you informed of this meeting?(Required)

Electronic mailing

At an ESH conference

At other conferences/congresses

Teaching faculty

Announcement in scientific journals

ESH website

Twitter

Facebook

Other:

Q4 Other(Required)

Please rate the lectures (+2, -1, 0, +1, +2)
-2 = poor | +2 = outstanding

Monday, September 6th, 2021
SESSION I – Diffuse large B-cell Lymphoma: How to optimize the benefit of CAR T-cell therapy?

Catherine Thieblemont

-2

-1

I didn't attend

Peter Borchmann

-2

-1

I didn't attend

Gilles Salles

-2

-1

I didn't attend

Robbie Majzner

-2

-1

I didn't attend

SESSION II – Diffuse large B-cell lymphoma: How to minimize potential risks of CAR T-cell therapy?

Ulrich Jäger

-2

-1

I didn't attend

Peter Schellongowski

-2

-1

I didn't attend

Stephan Grupp

-2

-1

I didn't attend

Marion Subklewe

-2

-1

I didn't attend

Christian Chabannon

-2

-1

I didn't attend

Tuesday, September 7th, 2021
SESSION III – Multiple Myeloma: targeting BCMA with bispecifics and CARs

Maria Victoria Mateos

-2

-1

I didn't attend

Sham Mailankody

-2

-1

I didn't attend

Michael Hudecek

-2

-1

I didn't attend

Maria Victoria Mateos

-2

-1

I didn't attend

DEBATE 1 – The future of myeloma therapy: how can T-cell engagement be integrated into current treatment strategies?

Hermann Einsele

-2

-1

I didn't attend

Sham Mailankody

-2

-1

I didn't attend

ROUNDTABLE 1 – Affordability of and access to CAR T-cell and bispecifics treatment

Carin Uyl-de Groot, Ananda Plate, Bertram Glass, Ana Hidalgo-Simon, Emanuele Ostuni

-2

-1

I didn't attend

3 Simultaneous Meet the Expert Sessions

1. Neuroblastoma (Franco Locatelli)

-2

-1

I didn't attend

2. CAR T-cells for solid childhood tumours (Concetta Quintarelli)

-2

-1

I didn't attend

3. Making CAR T-cells last (Karin Straathof)

-2

-1

I didn't attend

Wednesday, September 8th, 2021
WORKSHOP – Improving the Patient Journey

Ulrich Jäger, Peter Borchmann, Marie José Kersten, Jonathan Clark

-2

-1

I didn't attend

SESSION IV – Bispecific antibodies in the treatment of B-NHL

Marion Subklewe

-2

-1

I didn't attend

Stephan Schuster

-2

-1

I didn't attend

Richard Greil

-2

-1

I didn't attend

Martin Hutchings

-2

-1

I didn't attend

DEBATE 2 – Future 2nd and 3rd line treatment of r/r aggressive B-cell NHL: auto and allo-transplant, bispecifics, or CARs?

Bertram Glass

-2

-1

I didn't attend

Martin Hutchings

-2

-1

I didn't attend

Marie José Kersten

-2

-1

I didn't attend

ROUNDTABLE 2 – CARs in solid tumours

Franco Locatelli

-2

-1

I didn't attend

Concetta Quintarelli

-2

-1

I didn't attend

Karin Straathof

-2

-1

I didn't attend

4 Simultaneous Meet the Expert Sessions

1. NK cell CARs (Ulrike Köhl)

-2

-1

I didn't attend

2. Bispecific CAR T-cells (Peter Borchmann)

-2

-1

I didn't attend

3. Sleeping Beauty (Michael Hudecek)

-2

-1

I didn't attend

4. Point of care production of CAR T-cells (Alvaro Urbano-Ispizua)

-2

-1

I didn't attend

Thursday, September 9th, 2021
SESSION V – Acute lymphoblastic leukaemia (ALL): the role of CARs and Bispecifics - lessons from paediatric haematology

Jochen Büchner

-2

-1

I didn't attend

Peter Bader

-2

-1

I didn't attend

André Baruchel

-2

-1

I didn't attend

Sara Ghorashian

-2

-1

I didn't attend

Jochen Büchner

-2

-1

I didn't attend

SESSION VI – Perspectives: CARs and bispecifics for haematological malignancies

Marie José Kersten

-2

-1

I didn't attend

Paul Maciocia

-2

-1

I didn't attend

Chiara Bonini

-2

-1

I didn't attend

Cameron Turtle

-2

-1

I didn't attend

Keynote lecture

Carl June

-2

-1

I didn't attend

PLEASE PROVIDE US WITH YOUR COMMENTS:

Q5: Did this Conference meet your educational expectations?

Yes, absolutely

Yes

Not really

Not at all

Q6: Will you change something in your daily practice as a result of attending this conference?

Yes

Maybe

Q7: Do you consider that this virtual conference provided you with opportunities to ask questions?

Yes

Q8: Did you ask questions?

Yes

Q9: Were your questions answered?

Yes

Q10: Do you consider that this virtual conference provided you with opportunities for scientific interaction and networking?

With faculty members?

With peers?

Q11: Did you find the Multichoice Questionnaires and voting system useful to measure your knowledge?

Yes

Q12: What was your preferred session type? (several answers possible):

Plenary Sessions

Meet the Expert sessions

Poster walks

Q13: Did you find the e-platform:

Easy to navigate?

Attractive?

Q14: If ESH holds other virtual haematology conferences in your fields of interest, would you consider registering again?

Yes absolutely

Yes maybe

Probably not

Q15: Did you feel that the presentations at this ESH meeting were evidence-based and objective?

Yes

Q16: If you are a clinician, were they relevant to your clinical practice?

Yes

Q17: How do you evaluate the level of commercial biais at this ESH conference?

Absence of commercial biais

Average Level of commercial biais similar to other conferences organized by major academic institutions in the field

Higher than average level of commercial biais

Please feel free to comment:

CERTIFICATE OF ATTENDANCE

To obtain your Certificate of Attendance please fill the fields below:

First Name:(Required)

Last Name:(Required)

Email Address:(Required)

Verify Email Address:(Required)